AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
kanamycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, produced by Streptomyces strains | 1519 | 59-01-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | O |
| 1 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 90 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 30.96 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.26 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.99 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.10 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 52 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK5,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PDK4,PRKDC,TEK | 21 | |||
| kinase-selectivity-class | CHUK,MAP2K6,PDK1 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | Moderate | 0.65 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 13, 1973 | FDA | APOTHECON |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug resistance | 96.42 | 66.21 | 19 | 121 | 30430 | 90597877 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug resistance | 109.60 | 47.30 | 27 | 325 | 56347 | 110532600 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A07AA08 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Antibiotics |
| ATC | J01GB04 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE AMINOGLYCOSIDE ANTIBACTERIALS Other aminoglycosides |
| ATC | S01AA24 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics |
| FDA CS | M0000946 | Aminoglycosides |
| FDA EPC | N0000175477 | Aminoglycoside Antibacterial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D011500 | Protein Synthesis Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| CHEBI has role | CHEBI:176497 | geroprotector |
| CHEBI has role | CHEBI:76969 | bacterial metabolite |
Related Drugs by ATC class:
A07AA Antibiotics 12 drugs
J01GB Other aminoglycosides 12 drugs
S01AA Antibiotics 27 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Meningitis | indication | 7180009 | DOID:9471 |
| Bacterial septicemia | indication | 10001005 | DOID:0040085 |
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Bacterial pneumonia | indication | 53084003 | DOID:874 |
| Urinary tract infectious disease | indication | 68566005 | |
| Cholangitis | indication | 82403002 | DOID:9446 |
| Infection of bone | indication | 111253001 | |
| Infectious disease of abdomen | indication | 128070006 | |
| Infectious disorder of joint | indication | 363162000 | |
| Burn Wound Infections | indication | ||
| Preoperative Bowel Preparation | indication | ||
| Acute tuberculosis | off-label use | 25629007 | |
| Pulmonary tuberculosis | off-label use | 154283005 | DOID:2957 |
| Hypocalcemia | contraindication | 5291005 | |
| Parkinsonism | contraindication | 32798002 | |
| Dehydration | contraindication | 34095006 | |
| Tinnitus | contraindication | 60862001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Pregnancy, function | contraindication | 289908002 | |
| Vertigo | contraindication | 399153001 | |
| Disorder of the 8th Cranial Nerve | contraindication | ||
| Infant Botulism | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Bacterial infections | Indication |
| Dogs | Bacterial infections | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Kantrim 200 | Zoetis Inc. | 1 |
| Amforol Suspension | Zoetis Inc. | 3 |
| Kantrim Ophthalmic Ointment | Zoetis Inc. | 1 |
| Amforol Veterinary Oral Tablets | Zoetis Inc. | 3 |
| Kantrim Ophthalmic Solution | Zoetis Inc. | 1 |
| Kanfosone Ointment | Zoetis Inc. | 3 |
| Amphoderm Ointment | Zoetis Inc. | 3 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.29 | acidic |
| pKa2 | 13.57 | acidic |
| pKa3 | 7.97 | Basic |
| pKa4 | 7.46 | Basic |
| pKa5 | 6.99 | Basic |
| pKa6 | 5.55 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Gap junction beta-2 protein | Ion channel | IC50 | 5.03 | CHEMBL | |||||
| Gap junction alpha-1 protein | Ion channel | IC50 | 4.32 | CHEMBL | |||||
| Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B) | Enzyme | Km | 5.68 | WOMBAT-PK | |||||
| 3-oxoacyl-[acyl-carrier-protein] synthase 3 | Enzyme | IC50 | 5.17 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019795 | VUID |
| N0000147884 | NUI |
| D00866 | KEGG_DRUG |
| 8063-07-8 | SECONDARY_CAS_RN |
| 25389-94-0 | SECONDARY_CAS_RN |
| 4018142 | VANDF |
| 4019795 | VANDF |
| C0022487 | UMLSCUI |
| CHEBI:6104 | CHEBI |
| KAN | PDB_CHEM_ID |
| CHEMBL1384 | ChEMBL_ID |
| CHEMBL1446 | ChEMBL_ID |
| CHEMBL223520 | ChEMBL_ID |
| D007612 | MESH_DESCRIPTOR_UI |
| DB01172 | DRUGBANK_ID |
| 12132 | IUPHAR_LIGAND_ID |
| 870 | INN_ID |
| RUC37XUP2P | UNII |
| 6032 | PUBCHEM_CID |
| 1300476 | RXNORM |
| 3358 | MMSL |
| 4942 | MMSL |
| d00271 | MMSL |
| 002772 | NDDF |
| 004897 | NDDF |
| 387396008 | SNOMEDCT_US |
| 71451001 | SNOMEDCT_US |
| 8689007 | SNOMEDCT_US |
Pharmaceutical products:
None